Uncovering the Legacy of DES: A Call for Justice and Support for Victims
A former Love Island contestant, Maxwell Samuda, has spoken out about the health issues he believes are linked to his grandmother's use of a pregnancy drug called diethylstilbestrol (DES) in the 1970s. His mother and grandmother also attribute their health problems, including breast cancer and autoimmune conditions, to the drug. DES, a synthetic form of estrogen, was prescribed to women from the 1940s to the 1970s for various reasons, leading to infertility, reproductive abnormalities, and an increased risk of cancer. Despite being linked to cancer in the early 1970s, DES continued to be prescribed in Europe until the late 70s, causing long-term health issues for many individuals.
Maxwell's grandmother took DES during her second pregnancy to prevent miscarriage and later to stop breast milk production after the premature birth and passing of her son. She was diagnosed with breast cancer four years ago. His mother underwent multiple surgeries and treatments for pre-cancerous cells, fluid in her fallopian tubes, and autoimmune conditions. Maxwell himself had surgery as a baby for undescended testes and later discovered a benign lump and low sperm count. The family's health struggles have prompted them to call for a full public inquiry into the impact of DES exposure on their lives and the lives of others affected by the drug.
The DES Justice UK campaign group reports that approximately 300,000 women were given DES, leading to a range of health issues, including various cancers. Despite the known risks, DES continued to be prescribed, causing long-lasting health problems for those exposed to the drug. Maxwell's family's experiences highlight the need for awareness, support, and justice for individuals affected by DES exposure. The campaign group is advocating for a public inquiry and an NHS screening program to identify and support those at risk due to DES exposure.
The lack of a compensation scheme for DES victims in the UK contrasts with options available in other countries like the US and the Netherlands. The Department of Health and Social Care acknowledges the need for increased awareness and support for those affected by DES exposure, recognizing the long-lasting impacts of the drug on individuals and families. The call for justice and compensation for DES victims remains a pressing issue, as many continue to suffer from the consequences of a drug prescribed decades ago.